Patents by Inventor Jean-Marie Ruxer

Jean-Marie Ruxer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8309721
    Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: November 13, 2012
    Assignee: Sanofi
    Inventors: Jean-Marie Ruxer, Victor Certal, Marcel Alasia, Luc Bertin, Herve Minoux, Patrick Mailliet, Frank Halley, Maria Mendez-Perez
  • Patent number: 8178687
    Abstract: Pyrroloindoles of formula (I) are provided wherein Het is an aromatic or partially unsaturated, monocyclic or bicyclic heterocycle containing between 1 and 4 heteroatoms N, O or S, optionally substituted by R1 or R?1 which are the same or different; R is X-(A-B)n-CONH2, X-(A-B)n-O—CONH2, X-(A-B)n-NH—CONH2, X—(CH2)m-heterocycloalkyl, X(CH2)m-aryl and X—(CH2)m-heteroaryl wherein X is —O—C(O), —NH—C(O), NH—CS, —NH—CO—CH2-O—; —NH—COCH2-S—CH2-CO—NH—; —NH—CO—(CH2)2-SO2-; and —NH—CO—CH2-N(CH3)-CO—; A and B are the same or different and are each independently a single bond, CH2, CH-alkyl, and CH-aralkyl; n=1, 2 and m=0, 1; R1 and/or R?1 are H, halogen, CF3, nitro, cyano, alkyle, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, and carboxy, free or esterified by an alkyl, carboxamide, CONH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, and S(O2)-N(alkyl)2 group, all of said alkyl, alcoxy and alkylthio groups being optionally substituted themselves, said products being
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 15, 2012
    Assignee: Sanofi-Aventis
    Inventors: Marcel Alasia, Hervé Minoux, Jean-Marie Ruxer
  • Patent number: 8163750
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis
    Inventors: Fabienne Thompson, Patrick Mailliet, Jean-Marie Ruxer, Helene Goulaouic, Francois Vallee, Herve Minoux, Fabienne Pilorge, Luc Bertin, Stephane Hourcade, Maria Mendez-Perez, Peter Hamley
  • Publication number: 20120010241
    Abstract: The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R?1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A?), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.
    Type: Application
    Filed: March 18, 2010
    Publication date: January 12, 2012
    Applicant: SANOFI
    Inventors: Luc Bertin, Jean-Christophe Carry, Patrick Mailliet, Herve Minoux, Fabienne Pilorge, Jean-Marie Ruxer
  • Patent number: 8044074
    Abstract: The invention relates to compounds of formula I in which R1, R2, R3, R4, R5, R6 and X have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 25, 2011
    Assignee: Sanofi-Aventis
    Inventors: Joachim Brendel, Heinrich Christian Englert, Klaus Wirth, Michael Wagner, Jean-Marie Ruxer, Fabienne Pilorge
  • Publication number: 20110184015
    Abstract: Pyrroloindoles of formula (I) are provided wherein Het is an aromatic or partially unsaturated, monocyclic or bicyclic heterocycle containing between 1 and 4 heteroatoms N, O or S, optionally substituted by R1 or R?1 which are the same or different; R is X-(A-B)n-CONH2, X-(A-B)n-O—CONH2, X-(A-B)n-NH—CONH2, X—(CH2)m-heterocycloalkyl, X(CH2)m-aryl and X—(CH2)m-heteroaryl wherein X is —O—C(O), —NH—C(O), NH—CS, —NH—CO—CH2-O—; —NH—COCH2-S—CH2-CO—NH—; —NH—CO—(CH2)2-SO2-; and —NH—CO—CH2-N(CH3)-CO—; A and B are the same or different and are each independently a single bond, CH2, CH-alkyl, and CH-aralkyl; n=1,2 and m=0, 1; R1 and/or R?1 are H, halogen, CF3, nitro, cyano, alkyle, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, alkylthio, and carboxy, free or esterified by an alkyl, carboxamide, CONH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, and S(O2)-N(alkyl)2 group, all of said alkyl, alcoxy and alkylthio groups being optionally substituted themselves, said products being
    Type: Application
    Filed: December 16, 2010
    Publication date: July 28, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Marcel Alasia, Hervé Minoux, Jean-Marie Ruxer
  • Publication number: 20110166169
    Abstract: The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R?1; R is selected from the group comprising Formula (A?), (B), (C), (D), or (E), with R1 and/or R?1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.
    Type: Application
    Filed: September 14, 2010
    Publication date: July 7, 2011
    Applicant: sanofi-aventis
    Inventors: Jean-Marie RUXER, Victor CERTAL, Marcel ALASIA, Luc BERTIN, Herve MINOUX, Patrick MAILLIET, Frank HALLEY, Maria MENDEZ-PEREZ
  • Patent number: 7825264
    Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 2, 2010
    Assignee: sanofi-aventis
    Inventors: Joachim Brendel, Heinrich Christian Englert, Stefan Peukert, Klaus Wirth, Michael Wagner, Jean-Marie Ruxer, Fabienne Pilorge
  • Patent number: 7763621
    Abstract: A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: July 27, 2010
    Assignee: Galapagos SAS
    Inventors: Jean-Marie Ruxer, Jean-Michel Lefrancois, Bertrand Heckmann
  • Publication number: 20100130503
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R2?, L, Het, p and p? are as defined herein, compositions containing them, and their use as medicinal products.
    Type: Application
    Filed: November 24, 2009
    Publication date: May 27, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Fabienne THOMPSON, Patrick MAILLIET, Jean-Marie RUXER, Helene GOULAOUIC, François VALLEE, Herve MINOUX, Fabienne PILORGE, Luc BERTIN, Stephane HOURCADE, Maria MENDEZ-PEREZ, Peter HAMLEY
  • Patent number: 7674795
    Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: March 9, 2010
    Assignee: Aventis Pharma SA
    Inventors: Patrick Mailliet, Luc Bertin, Fabienne Thompson, Jean-Marie Ruxer, Fabienne Pilorge, Didier Benard, Hervé Minoux, Chantal Carrez, Hélène Goulaouic, Thierry Gouyon
  • Patent number: 7582640
    Abstract: A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: September 1, 2009
    Assignee: Galapagos SAS
    Inventors: Jean-Marie Ruxer, Jean-Michel Lefrancois, Bertrand Heckmann
  • Patent number: 7550453
    Abstract: The invention relates particularly to 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof as a medicament, particularly as anti-cancer agents.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: June 23, 2009
    Assignee: Aventis Pharma SA
    Inventors: Jidong Zhang, Neerja Bhatnagar, Jean-Marie Ruxer
  • Publication number: 20090149476
    Abstract: A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.
    Type: Application
    Filed: October 3, 2008
    Publication date: June 11, 2009
    Inventors: Jean-Marie Ruxer, Jean Michel Lefrancois, Bertrand Heckmann
  • Publication number: 20080188477
    Abstract: The invention relates to compounds of formula I in which R1, R2, R3, R4, R5, R6 and X have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Application
    Filed: December 12, 2007
    Publication date: August 7, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Joachim BRENDEL, Heinrich Christian ENGLERT, Klaus WIRTH, Michael WAGNER, Jean-Marie RUXER, Fabienne PILORGE
  • Publication number: 20080188520
    Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Application
    Filed: December 12, 2007
    Publication date: August 7, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Joachim BRENDEL, Heinrich Christian ENGLERT, Stefan PEUKERT, Klaus WIRTH, Michael WAGNER, Jean-Marie RUXER, Fabienne PILORGE
  • Publication number: 20080153837
    Abstract: This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.
    Type: Application
    Filed: November 14, 2007
    Publication date: June 26, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Luc BERTIN, Fabienne THOMPSON, Jean-Marie RUXER, Fabienne PILORGE, Didier BENARD, Herve MINOUX, Chantal CARREZ, Helene GOULAOUIC, Thierry GUYON
  • Publication number: 20080070960
    Abstract: This invention relates to 3-aryl-1,2-benzisoxazole derivatives of formula (I) to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.
    Type: Application
    Filed: August 20, 2007
    Publication date: March 20, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Luc BERTIN, Chantal CARREZ, Fabienne THOMPSON, Patrick MAILLIET, Jean-Marie RUXER
  • Publication number: 20070244087
    Abstract: The invention relates particularly to 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof as a medicament, particularly as anti-cancer agents.
    Type: Application
    Filed: May 24, 2007
    Publication date: October 18, 2007
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Jidong ZHANG, Neerja BHATNAGAR, Jean-Marie RUXER
  • Patent number: 7259159
    Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: August 21, 2007
    Assignees: Sanofi-Aventis Deutschland GmbH, Genentech Inc.
    Inventors: Anuschirwan Peyman, David Will, Thomas R Gadek, Robert McDowell, Jean Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle